Effects of hormone therapy on the central cholinergic neurotransmission of the Snell dwarf mouse.
Effects of growth and thyroid hormone therapy on central cholinergic neurotransmission has been followed in the cholinergic-deficient Snell dwarf mouse. Growth hormone and thyroxine can reverse the neurotransmission impairment even in adulthood. Furthermore, it appears that in the dw/dw mouse, hormone deficiency becomes determinant only after the critical period of neurogenesis, in a late postnatal developmental stage. At first sight, these observations show that the disturbed cholinergic neurotransmission of the mutant might be linked to the pituitary and thyroxine deficiency that is characteristic of this mouse. Hormone therapy selectively stimulates cholinergic activity in cholinergic-deficient structures, where it reactivates presynaptic markers. The differential responsiveness of the neuroanatomical and neurochemical targets could be linked to different regulatory hormone effects or to timing in respect to sensitivity to hormones during development.
D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000254:growth & development / Q000378:metabolism*; D002794:Choline / Q000378:metabolism*; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D005260:Female; D013006:Growth Hormone / Q000502:physiology*; D007700:Kinetics; D008297:Male; D051379:Mice; D008818:Mice, Neurologic Mutants / Q000254:growth & development* / Q000378:metabolism; D011869:Radioligand Assay; D011976:Receptors, Muscarinic / Q000378:metabolism; D013974:Thyroxine / Q000502:physiology*
D011976:Receptors, Muscarinic; D013006:Growth Hormone; D002795:Choline O-Acetyltransferase; D000110:Acetylcholinesterase; D002794:Choline; D013974:Thyroxine